Promedior names Suzanne L. Bruhn president and CEO

Wednesday, May 16, 2012 10:08 AM

Promedior, a Malvern, Penn.-based clinical stage biotech developing novel biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn, Ph.D., as president, CEO and to the board of directors.

Previously, Bruhn served at Shire as senior vice president of strategic planning and program management of the Human Genetic Therapies division, where she played a key leadership role in the development of multiple protein therapeutics for rare, orphan diseases with annual sales today of more than $1 billion. During her tenure at Shire and Transkaryotic Therapies (acquired by Shire in 2005), Bruhn was instrumental in advancing new compounds into clinical development and then continued to manage product strategy, portfolio management, program management and global regulatory affairs for the rare disease portfolio. Before serving with Shire, she served at Cytotherapeutics and played a key role developing the encapsulated cell technology platform for ophthalmic delivery. Bruhn currently serves on the board of directors of Raptor Pharmaceuticals, a public biotechnology company, and Crittenton Women's Union, a local non-profit organization helping low-income women.

Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. She is a seasoned biopharmaceutical leader with experience growing early stage R&D programs through clinical development and product commercialization.

Additionally, as part of the company's evolution, Promedior will move its headquarters and operations to the Boston area to access planned new hires in research and clinical drug development.

"Having recently completed the Series D financing in February and with the company positioned to move into later stage clinical studies within the next year, this was an appropriate time to transition to a new CEO,” said Jim Broderick, M.D., chairman of Promedior and partner at Morgenthaler Ventures. “Sue's strong business leadership and success in commercializing biologic drugs will be a great asset for the company and its growing team."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs